Inhibition of Tumor Necrosis Factor-α Reduces Atherosclerosis in Apolipoprotein E Knockout Mice
Top Cited Papers
- 1 November 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (11) , 2137-2142
- https://doi.org/10.1161/01.atv.0000143933.20616.1b
Abstract
Objective—Inflammation plays an important role in atherosclerosis. One of the most potent pro-inflammatory cytokines is tumor necrosis factor-α (TNF-α), a cytokine identified to have a pathogenic role in chronic inflammatory diseases such as rheumatoid arthritis (RA). The aim of the study was to evaluate the importance of TNF-α in atherogenesis.Methods and Results—Mice deficient in both apolipoprotein E (apoE) and TNF-α were compared regarding their atherosclerotic burden. Mice were fed a Western-style diet (WD) or normal chow. Mice deficient in both apoE and TNF-α exhibited a 50% (P=0.035) reduction of relative lesion size after 10 weeks of WD. Bone marrow transplantation ofapoEomice withapoEotnf-αobone marrow resulted in a 83% (P=0.021) reduction after 25 weeks on WD. InapoEknockout mice treated with recombinant soluble TNF receptor I releasing pellets, there was a reduction in relative lesion size after 25 weeks of 75% (P=0.018).Conclusions—These findings demonstrate that TNF-α is actively involved in the progression of atherosclerosis. Accordingly, TNF-α represents a possible target for prevention of atherosclerosis. This may be of particular importance in rheumatoid arthritis because these patients have an increased risk for cardiovascular disease.Keywords
This publication has 25 references indexed in Scilit:
- Exclusive expression of transmembrane TNF-α in mice reduces the inflammatory response in early lipid lesions of aortic sinusAtherosclerosis, 2004
- Anti–tumor necrosis factor therapiesCurrent Opinion in Rheumatology, 2001
- TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanerceptExpert Opinion on Pharmacotherapy, 2001
- Soluble cytokine receptors: novel immunotherapeutic agentsExpert Opinion on Investigational Drugs, 2000
- Unlinking Tumor Necrosis Factor Biology from the Major Histocompatibility Complex: Lessons from Human Genetics and Animal ModelsAmerican Journal of Human Genetics, 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- LONG-TERM PROTECTION AGAINST THE EFFECTS OF TUMOUR NECROSIS FACTOR BY CONTROLLED DELIVERY OF THE SOLUBLE p55 TNF RECEPTORCytokine, 1996
- Enhanced Expression of Vascular Matrix Metalloproteinases Induced In Vitro by Cytokines and in Regions of Human Atherosclerotic LesionsaAnnals of the New York Academy of Sciences, 1994
- Cardiovascular Mortality in Patients with Rheumatoid ArthritisCardiology, 1989
- TUMOR NECROSIS, CACHEXIA, SHOCK, AND INFLAMMATION: A COMMON MEDIATORAnnual Review of Biochemistry, 1988